Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Marco MontilloEnrica Morra

Abstract

Treatment with alemtuzumab has resulted in negative responses for minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). In a prior analysis we demonstrated that it is possible to achieved MRD negativity, as assessed by polyclonality of immunoglobulin heavy chain after consolidation with alemtuzumab. This phase II study evaluated 34 patients with CLL who received alemtuzumab consolidation in an effort to improve the quality of their response to fludarabine-based induction. Subsequent peripheral blood stem-cell (PBSC) collection and transplantation, tolerability, and pharmacokinetics also were assessed. Thirty-four patients younger than 65 years who had a clinical response to fludarabine-based induction therapy received alemtuzumab 10 mg subcutaneously three times per week for 6 weeks. PBSCs were collected after mobilization with cytarabine and granulocyte colony-stimulating factor. Blood samples for pharmacokinetics study were taken between days 1 and 31. The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity. The most common adverse events were injection-site reactions and fever. Cyto...Continue Reading

References

Mar 1, 1990·Tissue Antigens·G HaleH Waldmann
Mar 17, 1995·The Journal of Biological Chemistry·A TreumannM A Ferguson
Jul 5, 2001·Journal of Clinical Epidemiology·V LevyUNKNOWN French Cooperative CLL Group
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J-F RossiS M Tollerfield
May 5, 2004·Seminars in Oncology·Alessandra Ferrajoli, Susan M O'Brien
Aug 25, 2004·Hematology/oncology Clinics of North America·Emili Montserrat
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen

❮ Previous
Next ❯

Citations

Apr 4, 2009·Targeted Oncology·Alfonso Quintás-Cardama, Susan O'Brien
Jan 1, 2008·Current Hematologic Malignancy Reports·Andy C Rawstron, Peter Hillmen
Jan 1, 2008·Current Hematologic Malignancy Reports·Carmen Diana SchweighoferClemens-Martin Wendtner
Jan 1, 2009·Current Hematologic Malignancy Reports·Thomas ElterClemens-Martin Wendtner
Apr 29, 2010·Current Hematologic Malignancy Reports·Abraham M VarghesePeter Hillmen
Dec 15, 2010·Current Hematologic Malignancy Reports·Xavier C BadouxWilliam G Wierda
Jan 13, 2012·Current Hematologic Malignancy Reports·Leopold SellnerThorsten Zenz
Nov 29, 2012·Current Hematologic Malignancy Reports·L SellnerT Zenz
Oct 20, 2010·Nature Reviews. Clinical Oncology·Paula Cramer, Michael Hallek
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Nov 21, 2007·Hematology·Tait D Shanafelt, Neil E Kay
Jan 18, 2011·Hematology·Alessandra Ferrajoli
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas S LinRichard A Larson
Jul 10, 2010·OncoTargets and Therapy·Carmen Diana Schweighofer, Clemens-Martin Wendtner
May 14, 2009·Therapeutics and Clinical Risk Management·Francesca RicciMarco Montillo
Nov 17, 2009·Drugs·Tadeusz RobakPawel Robak
Dec 4, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Annamaria Nosari
Feb 7, 2007·Future Oncology·Danelle F James, Thomas J Kipps
Feb 1, 2007·Current Hematologic Malignancy Reports·Rifca Le Dieu, John G Gribben
Dec 5, 2008·Leukemia & Lymphoma·Thomas ElterClemens Wendtner
Apr 12, 2008·Expert Review of Anticancer Therapy·Kevin Boyd, Claire E Dearden
Jul 1, 2008·Expert Review of Anticancer Therapy·Tadeusz Robak
Oct 6, 2006·Expert Review of Anticancer Therapy·Marco MontilloAlessandra Tedeschi
Feb 21, 2007·Expert Opinion on Biological Therapy·Yiwen Li, Zhenping Zhu
Nov 1, 2007·Expert Opinion on Investigational Drugs·Mohamed A Kharfan-DabajaEdgardo S Santos
Nov 24, 2007·Expert Opinion on Biological Therapy·Michael BoyiadzisSteven Pavletic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.